Nov 27, 2024 / 07:00AM GMT
Operator
Greetings, and welcome to the Nykode Therapeutics third-quarter 2024 conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to your host, CEO, Michael Engsig. Please go ahead.
Michael Engsig - Nykode Therapeutics ASA - Chief Executive Officer
Thank you very much, Kevin, and a warm welcome to everybody this early hours of Scandinavia to dial in from there. Go to the next slide.
Here, I just want to remind everybody of our forward-looking statements. So we are familiar with the wording on that. And on that note, we will move forward. I'm very pleased to have with me today here in the room, Agnete Fredriksen, Chief Scientific Officer and Business Development; Harald Gurvin, Chief Financial Officer. And today, we also are pleased to have Martin Nicklasson, the Chairman of the Board.
And Martin, I'm going to hand over to you to kick us off for this quarterly update for third-quarter 2024.
Martin Nicklasson - Nykode
Q3 2024 Nykode Therapeutics ASA Earnings Call Transcript
19 hours ago
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers